On November 21, 2022 Scorpion Therapeutics, Inc. ("Scorpion"), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, reported that it will present preclinical data on STX-478, its potential best-in-class mutant-selective PI3Kα inhibitor, in a poster session at San Antonio Breast Cancer Symposium ("SABCS") in San Antonio, Texas, taking place December 6 – 10, 2022 (Press release, Scorpion Therapeutics, NOV 21, 2022, View Source [SID1234624310]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
STX-478 is a highly selective, allosteric and CNS-penetrant inhibitor of mutant PI3Kα, designed to improve outcomes in patients harboring tumors with prevalent PI3Kα kinase or helical domain mutations. Scorpion has completed IND-enabling studies for STX-478 and expects to submit an IND application to the U.S. Food and Drug Administration ("FDA") in the first quarter of 2023.
"We are excited to present preclinical data that further support STX-478’s potential as a best-in-class PI3Kα inhibitor and advances its development as a novel therapeutic for the treatment of many solid tumors that are underserved by existing options," said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion Therapeutics. "Despite PI3Kα being one of the most highly-mutated targets in cancer, currently available therapies suffer from serious limitations, including a lack of wild-type selectivity, which induces metabolic dysfunction and causes dose-limiting toxicities, and an inability to penetrate the central nervous system (CNS), which leaves brain metastases – a common occurrence in solid tumor patients – unaddressed. We are confident that STX-478 can address these challenges through superior monotherapy activity, as well as in combination with relevant co-treatments, without sacrificing tolerability."